603108 润达医疗
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,470,488-16.08%8,311,7809,147,37310,494,4198,860,108
减:营业总成本3,514,568-9.87%7,994,7838,651,9939,643,2848,160,246
    其中:营业成本2,743,784-8.98%6,203,4926,718,3717,557,0676,468,094
               财务费用131,644-17.08%313,435316,682323,591291,634
               资产减值损失(46)-64.95%(36,170)(34,500)(40,772)(7,299)
公允价值变动收益------------
投资收益47,447-32.63%109,821231,999137,048137,876
    其中:对联营企业和合营企业的投资收益46,571-33.73%108,488139,609138,057133,628
营业利润(51,490)-122.17%354,060646,803816,373777,798
利润总额(53,060)-122.41%345,542655,555819,651780,456
减:所得税费用46,422-45.09%156,084212,920164,541182,255
净利润(99,482)-165.33%189,458442,636655,110598,201
减:非控股权益21,170-65.28%134,177169,339237,364217,972
股东净利润(120,652)-232.14%55,281273,296417,746380,229

市场价值指针
每股收益 (元) *-0.200-233.33%0.0900.4700.7200.660
每股派息 (元) *----0.0300.1000.150--
每股净资产 (元) *6.906-3.22%7.1367.0606.5195.785
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容